Accretion Pharmaceuticals Ltd
Incorporated in 2012, Accretion Pharmaceuticals Limited is a pharmaceutical company that manufactures and sells tablets, capsules, and other healthcare products.[1]
- Market Cap ₹ 70.6 Cr.
- Current Price ₹ 63.6
- High / Low ₹ 102 / 53.8
- Stock P/E 7.78
- Book Value ₹ 41.9
- Dividend Yield 0.00 %
- ROCE 46.4 %
- ROE 65.4 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Debtor days have improved from 116 to 74.2 days.
- Company's working capital requirements have reduced from 127 days to 65.3 days
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|
| 13.35 | 57.38 | 82.55 | |
| 10.78 | 45.49 | 67.94 | |
| Operating Profit | 2.57 | 11.89 | 14.61 |
| OPM % | 19.25% | 20.72% | 17.70% |
| 0.05 | 0.09 | 0.19 | |
| Interest | 0.40 | 1.44 | 1.11 |
| Depreciation | 0.22 | 0.77 | 0.81 |
| Profit before tax | 2.00 | 9.77 | 12.88 |
| Tax % | 25.00% | 30.40% | |
| 1.49 | 6.79 | 9.08 | |
| EPS in Rs | 3.72 | 8.31 | 9.57 |
| Dividend Payout % | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 159% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 130% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 65% |
Balance Sheet
Figures in Rs. Crores
| Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|
| Equity Capital | 4.00 | 8.17 | 11.12 |
| Reserves | 1.49 | 7.12 | 35.46 |
| 13.48 | 14.10 | 7.85 | |
| 8.47 | 10.48 | 4.64 | |
| Total Liabilities | 27.44 | 39.87 | 59.07 |
| 5.25 | 6.09 | 8.67 | |
| CWIP | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 |
| 22.19 | 33.78 | 50.40 | |
| Total Assets | 27.44 | 39.87 | 59.07 |
Cash Flows
Figures in Rs. Crores
| Mar 2024 | Mar 2025 | |
|---|---|---|
| -11.51 | 5.75 | |
| -5.48 | -1.61 | |
| 17.08 | -4.18 | |
| Net Cash Flow | 0.09 | -0.04 |
Ratios
Figures in Rs. Crores
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Debtor Days | 158.58 | 74.17 |
| Inventory Days | 564.06 | 188.49 |
| Days Payable | 256.32 | 69.41 |
| Cash Conversion Cycle | 466.31 | 193.25 |
| Working Capital Days | 189.47 | 65.33 |
| ROCE % | 46.36% |
Insights
In beta| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Capsule Installed Capacity Million Units |
|
|||
| Capsules Capacity Utilization % |
||||
| Capsules Utilized Capacity Crore Units |
||||
| Oral Liquid Capacity Utilization % |
||||
| Oral Liquid Installed Capacity Million Bottles |
||||
| Oral Liquids Utilized Capacity Crore Units |
||||
| Tablet Installed Capacity Million Units |
||||
| Tablets Capacity Utilization % |
||||
| Tablets Utilized Capacity Crore Units |
||||
| Working Capital Days Days |
||||
| Domestic Presence (Indian States) Number |
||||
Documents
Announcements
-
Analysts/Institutional Investor Meet/Con. Call Updates
10 March 2026 - Plant visit with group of investors/analysts scheduled for 13 March 2026.
-
Analysts/Institutional Investor Meet/Con. Call Updates
3 March 2026 - Management to participate in Arihant Capital Bharat Connect virtual conference on 11 March 2026, 10:00 AM.
-
Clarification - Financial Results
19 January 2026 - Exchange has sought clarification from Accretion Pharmaceuticals Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (LODR) Regulations, 2015. On …
-
Action(s) taken or orders passed
7 January 2026 - SEBI order (07-Jan-2026) imposes Rs.1,00,000 penalty for IPO disclosure violation.
-
Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter
3 January 2026 - Exempt from SEBI Reg 27(2) reporting for quarter ended 31-Dec-2025; certificate attached.
Concalls
-
Nov 2025Transcript PPT REC
Business Profile[1]
The company manufactures pharmaceutical formulations, including both generic and branded products. It offers contract and third-party manufacturing services for domestic and international markets. Its clientele includes private institutions, government sectors (state and central), and reputed pharmaceutical companies.